Novel Attenuated Chikungunya Vaccine Candidates Elicit Protective Immunity in C57BL/6 mice
David Hallengard, Maria Kakoulidou, Aleksei Lulla, Beate M Kuemmerer, Daniel X Johansson, Margit Mutso, Valeria Lulla, John K Fazakerley, Pierre Roques, Roger Le Grand, Andres Merits, Peter Liljestrom
JOURNAL OF VIROLOGY | AMER SOC MICROBIOLOGY | Published : 2014
UNLABELLED: Chikungunya virus (CHIKV) is a reemerging mosquito-borne alphavirus that has caused severe epidemics in Africa and Asia and occasionally in Europe. As of today, there is no licensed vaccine available to prevent CHIKV infection. Here we describe the development and evaluation of novel CHIKV vaccine candidates that were attenuated by deleting a large part of the gene encoding nsP3 or the entire gene encoding 6K and were administered as viral particles or infectious genomes launched by DNA. The resulting attenuated mutants were genetically stable and elicited high magnitudes of binding and neutralizing antibodies as well as strong T cell responses after a single immunization in C57B..View full abstract
Awarded by European Union
Awarded by Biotechnology and Biological Sciences Research Council
This work was supported by the European Union FP7 project "Integrated Chikungunya Research" (ICRES), grant agreement number 261202, and by the Swedish Research Council.